• Vaccine Name: live attenuated Brucella melitensis purE deletion mutant vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009107
• Type: Live attenuated vaccine
• Status: Research
• Host Species for Licensed Use: Goat
• Antigen: purE deletion mutant
• Preparation: Genetic deletion mutant (deltapurE201) of Brucella melitensis strain 16M. (Cheville et al, 1996)
• Description: Young goats were inoculated subcutaneously with the purE deletion mutant to evaluate host responses. Efficacy: The purE mutant was cleared from visceral tissues by PID 84, with no bacteria detected in mammary lymph nodes or spleen at necropsy; it produced immune responses and less severe pathologic changes compared to the virulent parental strain. Immune response: Serum antibody titers peaked at PID 14; marked germinal center formation and medullary plasmacytosis by PID 28; brucellar antigens detected in capsular granulomas; bacteria found mainly in macrophages and small lymphocytes. (Cheville et al, 1996)

Goat Response

• Immune Response: Serum antibody titers peaked at PID 14; marked germinal center formation and medullary plasmacytosis by PID 28; brucellar antigens detected in capsular granulomas; bacteria found mainly in macrophages and small lymphocytes. (Cheville et al, 1996)
• Efficacy: The purE mutant was cleared from visceral tissues by PID 84, with no bacteria detected in mammary lymph nodes or spleen at necropsy; it produced immune responses and less severe pathologic changes compared to the virulent parental strain. (Cheville et al, 1996)
• Description: Subcutaneous inoculation of young goats; monitoring of bacterial persistence in lymph nodes and spleen; histopathology and immunoperoxidase detection of brucellar antigens; ultrastructural examination of infected cells. (Cheville et al, 1996)